✦ LIBER ✦

Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer

✍ Scribed by Akihisa Fujita; Hirotsugu Takabatake; Shigeru Tagaki; Kyuhichiro Sekine

Publisher: Springer
Year: 2000
Tongue: English
Weight: 80 KB
Volume: 45
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800050041

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of etoposide, cisplatin an

Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer

✍ E. Briasoulis; E. Samantas; H. Kalofonos; D. Skarlos; T. Makatsoris; C. Christod 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 376 KB

Phase II trial of combination chemothera

Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer

✍ Yoichi Nakanishi; Yuji Kawarada; Nobuyuki Hirose; Kiyoshi Ninomiya; Masayuki Miy 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 340 KB

Biweekly docetaxel-irinotecan with filgr

Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study

✍ Giuseppe Frasci; Pasquale Comella; Renato Thomas; Maurizio Bonito; Liliana Lapen 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 197 KB

Phase I studies of imatinib mesylate com

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma

✍ Faye M. Johnson; Lee M. Krug; Hai T. Tran; Stephanie Shoaf; Victor G. Prieto; Ph 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 329 KB 👁 2 views

Phase II trial of irinotecan, paclitaxel

Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma

✍ Mark A. Socinski; Alan B. Sandler; Valerie K. Israel; Heidi H. Gillenwater; Lang 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract ## BACKGROUND This Phase II multicenter, open‐label, single‐arm study evaluated the efficacy and safety of a three‐drug combination of irinotecan (CPT‐11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC). ## METHODS Patients received repeated 21‐day cycle

Phase I study of vinorelbine and irinote

Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer

✍ Nanae Tomonaga; Yoichi Nakamura; Hiroshi Soda; Seiji Nagashima; Hirofumi Nakano; 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 273 KB